The novel formulation hit peak activity at nine minutes, less than half the time taken for a commercially available formulation.
List view / Grid view
Filter the results
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
An assay assessing the level of programmed death ligand 1 (PD-L1) could help to determine the method of treatment for lung cancer patients...
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer's disease...
Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.